Pharma’s future: More with less
Published on October 1, 2024
2023 saw the biopharmaceutical industry spend a record $300bn on R&D activities, reinvesting approximately 30% of prescription revenues to secure the next generation of therapies. Yet, recent weeks have seen falling valuations and stark anecdotes from contract research organizations as their main client base – large pharma companies – have tightened the belt on early […]